Biodesix Inc (BDSX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biodesix Inc (BDSX) has a cash flow conversion efficiency ratio of 5.156x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.88 Million) by net assets ($-1.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biodesix Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Biodesix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read BDSX total liabilities for a breakdown of total debt and financial obligations.
Biodesix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biodesix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
meerecompany Incorporated
KQ:049950
|
-0.118x |
|
J W Mays Inc
NASDAQ:MAYS
|
0.037x |
|
Tradetool Auto Co Ltd
TWO:3685
|
-0.003x |
|
European Residential Real Estate Investment Trust
TO:ERE-UN
|
0.032x |
|
Loxley Public Company Limited
F:NVAI
|
0.112x |
|
PP Presisi Tbk PT
JK:PPRE
|
-0.047x |
|
Consolidated Construction Consortium Limited
NSE:CCCL
|
-0.262x |
|
Azaria Rental SOCIMI S.A.
MC:YAZR
|
-0.025x |
Annual Cash Flow Conversion Efficiency for Biodesix Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Biodesix Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Biodesix Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $20.88 Million | $-48.65 Million | -2.330x | +53.33% |
| 2023-12-31 | $4.58 Million | $-22.87 Million | -4.993x | -128.80% |
| 2022-12-31 | $20.61 Million | $-44.97 Million | -2.182x | -52.55% |
| 2021-12-31 | $19.73 Million | $-28.22 Million | -1.431x | -175.65% |
| 2020-12-31 | $41.17 Million | $-21.37 Million | -0.519x | -645.97% |
| 2019-12-31 | $-228.54 Million | $-21.73 Million | 0.095x | +6.50% |
| 2018-12-31 | $-198.03 Million | $-17.68 Million | 0.089x | -- |
About Biodesix Inc
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also pro… Read more